Erratum: New and emerging treatments for Alzheimer's disease (Expert Review of Neurotherapeutics (2012) 12:5 (533-543) DOI: 10.1586/ern.12.43);New and emerging treatments for Alzheimers disease

Expert Review of Neurotherapeutics

Volumn 12, Issue 5, 2012, Pages 535-543

  Corbett, Anne ^a   Smith, Jessica ^a   Ballard, Clive ^a,b  

^a ALZHEIMER'S SOCIETY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's; amyloid; dementia; future; immunotherapy; repositioning; tau; therapy; treatment

Indexed keywords

ALZHEIMER DISEASE VACCINE; BAPINEUZUMAB; BRYOSTATIN 1; CLIOQUINOL; CRENEZUMAB; DIMEBON; DONEPEZIL; EHT 0202; ETAZOLATE; EXENDIN 4; GALANTAMINE; GANTENERUMAB; GSK 933776; HOMOTAURINE; LADOSTIGIL; LIRAGLUTIDE; LITHIUM; MEMANTINE; METHYLENE BLUE; MONOCLONAL ANTIBODY; PIOGLITAZONE; PLACEBO; PONEZUMAB; QS 21; RIVASTIGMINE; RO 4909832; ROSIGLITAZONE; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE REHABILITATION; EDEMA; EYE TOXICITY; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MENINGOENCEPHALITIS; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84860554747     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.827493     Document Type: Erratum

References (91)

1. Wimo A, Prince M. World Alzheimer Report 2010. Alzheimer's Disease International, London, UK (2010)
2. Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem. Res. 33(3), 526-532 (2008)
3. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol. 41(6), 1261-1268 (2009)
4. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1(8004), 189 (1977)
5. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 1, CD001747 (2006)
6. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2, CD001191 (2009)
7. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD001190 (2006)
8. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr. 21(5), 813-824 (2009)
9. Gauthier S, Feldman H, Hecker J et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Donepezil MSAD Study Investigators Group. Int. Psychogeriatr. 14(4), 389-404 (2002)
10. Ballard C, Sorensen S, Sharp S. Pharmacological therapy for people with Alzheimer's disease: The balance of clinical effectiveness, ethical issues and social and healthcare costs. J. Alzheimer's Dis. 12(1), 53-59 (2007)
11. Ballard CG, Chalmers KA, Todd C et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 68(20), 1726-1729 (2007)
12. Chalmers KA, Wilcock GK, Vinters HV et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J. Neurol. 256(5), 717-720 (2009)
13. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biological Psych. 31(4), 337-350 (1992)
14. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291(3), 317-324 (2004)
15. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 22(3), 209-221 (2008)
16. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. J. Clin. Psych. 69(3), 341-348 (2008)
17. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-Analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 3(1), 7-17 (2007)
18. Howard R, McShane R, Lindesay J et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 366, 893-903 (2012)
19. Hock C, Maddalena A, Raschig A et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10, 1-6 (2003)
20. Bodick NC, Offen WW, Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54(4), 465-473 (1997)
21. Sarazin M, De Souza LC, Lehéricy S, Dubois B. Clinical and Research diagnostic Criteria for Alzheimer's Disease. Neuroimaging Clin. N. Am. 22(1), 23-32 (2012)
22. Clare L, Linden DE, Woods RT et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: A single-blind randomized controlled trial of clinical efficacy. Am. J. Geriatric Psych. 18(10), 928-939 (2010)
23. Yu F, Rose KM, Burgener SC et al. Cognitive training for early-stage Alzheimer's disease and dementia. J. Gerontological Nursing 35, 23-29 (2009)
24. Spector A, Thorgrimsen L, Woods B et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial. Br. J. Psych. 183, 248-254 (2003)
25. Owen AM, Hampshire A, Grahn JA et al. Putting brain training to the test. Nature 465(7299), 775-778 (2010)
26. Erickson KI, Voss MW, Prakash RS et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl Acad. Sci. USA 108(7), 3017-3022 (2011)
27. Baker LD, Frank LL, Foster-Schubert K et al. Effects of aerobic exercise on mild cognitive impairment: A controlled trial. Arch. Neurol. 67(1), 71-79 (2010)
28. Lautenschlager NT, Cox KL, Flicker L et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial. JAMA 300(9), 1027-1037 (2008)
29. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev. Neurother. 9(5), 661-679 (2009)
30. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5(3), 481-489 (2008)
31. Gold M, Alderton C, Zvartau-Hind ME et al. Effects of rosiglitazone as monotherapy in apoE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement. 5(4), 86 (2009)
32. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. 10(10), 1657-1664 (2009)
33. Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 302(23), 2557-2564 (2009)
34. Tariot PN, Schneider LS, Cummings J et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. General Psych. 68(8), 853-861 (2011)
35. Mudher A, Shepherd D, Newman TA et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psych. 9(5), 522-530 (2004)
36. Leroy K, Ando K, Heraud C et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J. Alzheimer's Dis. 19(2), 705-719 (2010)
37. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. Feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriatric Psych. 23(7), 704-711 (2008)
38. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14(9), 894 (2008)
39. Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimer's disease. Expert Opin. Ther. Targets 12(6), 693-704 (2008)
40. Marcade M, Bourdin J, Loiseau N et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106(1), 392-404 (2008)
41. Desire L, Marcade M, Peillon H, Drouin D, Sol O. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer's disease. Alzheimers Dement. 5(4), 255 (2009)
42. Jones RW. Dimebon disappointment. Alzheimers Res. Ther. 2(5), 25 (2010)
43. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31(17), 6587-6594 (2011)
44. Li Y, Duffy KB, Ottinger MA, Ray B et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimer's Dis. 19(4), 1205-1219 (2010)
45. Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 26(1), 273-281 (2007)
46. Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch. Neurol. 63(5), 686-692 (2006)
47. Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465 (2010)
48. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci. 25(12), 609-612 (2004)
49. Loeb MB, Molloy DW, Smieja M et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatrics Soc. 52(3), 381-387 (2004)
50. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007)
51. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9), 1553-1562 (2005)
52. Holmes C, Boche D, Wilkinson D et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372(9634), 216-223 (2008)
53. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of affitope vaccines for Alzheimer's disease (AD) - from concept to clinical testing. J. Nutr Health Aging 13(3), 264-267 (2009)
54. Winblad B, Minthon L, Floesser A et al. Results of the first-in-man study with the active Ab immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement. 5(4), 113 (2009)
55. Wilcock DM, Colton CA. Anti-Amyloid-beta immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials. J. Alzheimers Dis. 15(4), 555-569 (2008)
56. Relkin NR, Szabo P, Adamiak B et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30(11), 1728-1736 (2009)
57. Siemers ER, Friedrich S, Dean RA et al. Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement. 4(4), 774 (2008).
58. Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24), 2061-2070 (2009)
59. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101-112 (2007)
60. Shankar GM, Li, S, Mehta TH et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008)
61. Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67(10), 1757-1763 (2006)
62. Aisen P, Gauthier S, Ferris S et al. A Phase III, placebo-controlled, double-blind, randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer's disease (the Alphase study). Presented at: 61st American Academy of Neurology Annual Meeting. WA, USA, 25 April-2 May 2009 (Abstract S32.003)
63. McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12(7), 801-808 (2006)
64. Garzone P, Koller M, Pastrak A et al. Oral amyloid anti-Aggregating agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimers Dement. 5(4), 323 (2009)
65. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot Phase 2 clinical trial. Arch. Neurol. 60(12), 1685-1691 (2003)
66. Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7(9), 779-786 (2008)
67. Wilcock DM, Colton CA. Anti-Ab immunotherapy in Alzheimer's disease; relevance of transgenic mouse studies to clinical trials J. Alzheimers Dis. 15(4), 555-569 (2008)
68. Weinreb O, Amit T, Bar-Am O, Youdim MB. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int. Rev. Neurobiol. 100, 191-215 (2011)
69. Maher-Edwards G, Zvartau-Hind M, Hunter AL et al. Double-blind, controlled Phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res. 7(5), 374-385 (2010)
70. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Targeting 17(8), 564-574 (2009)
71. Blurton-Jones M, Kitazawa M, Martinez- Coria H et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl Acad. Sci. USA 106(32), 13594-13599 (2009)
72. Yurko-Mauro K, McCarthy D, Rom D et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 6(6), 456-464 (2010)
73. Kotani S, Sakaguchi E, Warashina S et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 56(2), 159-164 (2006)
74. Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 304(17), 1903-1911 (2010)
75. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch. Neurol. 63(10), 1402-1408 (2006)
76. Freund-Levi Y, Basun H, Cederholm T et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 23(2), 161-169 (2008)
77. Lloret A, Badía MC, Mora NJ et al. Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 17(1), 143-149 (2009)
78. Remington R, Chan A, Paskavitz J et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: A placebo-controlled pilot study. Am. J. Alzheimers Dis. Other Demen. 24(1), 27-33 (2009)
79. Tong XK, Nicolakakis N, Fernandes P et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 35(3), 406-414 (2009)
80. Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12), 956-964 (2010)
81. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289(21), 2819-2826 (2003)
82. Reines SA, Block GA, Morris JC et al. Rofecoxib: No effect on Alzheimer's disease in a 1 year, randomized, blinded, controlled study. Neurology 62(1), 66-71 (2004)
83. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43(8), 1609-1611 (1993)
84. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst. Rev. 2, CD003673 (2002)
85. De Jong D, Jansen R, Hoefnagels W et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial. PLoS ONE 3(1), e1475 (2008)
86. Schmidt AM, Sahagan B, Nelson RB et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr. Opin. Investig Drugs 10(7), 672-680 (2009)
87. Bates KA, Verdile G, Li QX et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: Implications for therapeutic design and diagnostic tests. Mol. Psych. 14(5), 469-486 (2009)
88. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl. 1), 2628-2631 (2004)
89. Shi JQ, Shen W, Chen J et al. Anti-TNF-A reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 1368, 239-247 (2011)
90. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized controlled trial. Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. CMAJ 174(8), 1099-1105 (2006)
91. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 7, 26 (2007)